Evidence map›Paper›PMID 35323230›Full record

ArticleJournal of functional biomaterials2022

Investigating Cancerous Exosomes' Effects on CD8+ T-Cell IL-2 Production in a 3D Unidirectional Flow Bioreactor Using 3D Printed, RGD-Functionalized PLLA Scaffolds.

Daniel Karami, Akhil Srivastava, Rajagopal Ramesh, Vassilios I Sikavitsas

Open access · goldAbstract read
In one paragraph

Article in Journal of functional biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Daniel KaramiSchool of Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK 73019, USA.
Akhil SrivastavaDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-2015-259X
Rajagopal RameshDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0002-7658-5338
Vassilios I SikavitsasSchool of Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK 73019, USA.
University of Oklahoma Health Sciences Center · USUniversity of Oklahoma · US

Funding

Exosomes as carriers of cancer therapeuticsR01CA254192 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAMESH, RAJAGOPAL · 2021 to 2025
$2.8M
An improved IL-24 gene-based therapeutic for cancerR01CA233201 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAMESH, RAJAGOPAL · 2019 to 2023
$1.7M
NCI NIH HHS R01 CA233201NCI NIH HHS R01 CA254192University of Oklahoma Institute of Biomedical Engineering Sciences and Technology Seed Grant
6 · The paper itself

Abstract

Exosomes from cancer cells are implicated in cancer progression and metastasis, carrying immunosuppressive factors that limit the antitumor abilities of immune cells. The development of a real-time, 3D cell/scaffold construct flow perfusion system has been explored as a novel tool in the study of T-cells and exosomes from cancer cells. Exosomes from human lung cancer (H1299 and A549) cells were co-cultured in a unidirectional flow bioreactor with CD8+ T-cells immobilized onto 3D-printed RGD-functionalized poly(L-lactic) acid (PLLA) scaffolds and assessed for IL-2 production. The IL-2 production was investigated for a wide range of T-cell to exosome ratios. With the successful incorporation of the RGD binding motif onto the PLLA surface at controllable densities, CD8+ T-cells were successfully attached onto 2D disks and 3D printed porous PLLA scaffolds. T-cell attachment increased with increasing RGD surface density. The diameter of the attached T-cells was 7.2 ± 0.2 µm for RGD densities below 0.5 nmoles/mm

Indexed as

bioreactorcancerexosomefluid flowsurface modification

Identifiers

PMID35323230
PMCPMC8950614
OpenAlexW4220684754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.